0000000000003236

AUTHOR

Azeem Latib

0000-0001-9035-343x

showing 26 related works from this author

Coronary artery bypass graft versus percutaneous coronary intervention with drug-eluting stent implantation for diabetic patients with unprotected le…

2013

textabstractAims: Data regarding the impact on clinical outcomes of PCI with DES implantation vs. CABG to treat unprotected left main coronary artery (ULMCA) disease in diabetic patients are still insufficient. The present study evaluated the short-term and long-term results of percutaneous and surgical revascularisation in diabetic patients with ULMCA disease in a large population. Methods and results: A total of 826 diabetic patients with ULMCA stenosis who received DES (n=520) or underwent CABG (n=306) were selected and analysed from the DELTA registry. In-hospital MACCE was significantly higher in the CABG group, mainly driven by a higher incidence of MI. At four-year follow-up, freedom…

medicine.medical_specialtyPercutaneousmedicine.medical_treatmentMedizinCoronary Artery DiseasePercutaneous Coronary InterventionSDG 3 - Good Health and Well-beingInternal medicineDiabetes mellitusmedicineDiabetes MellitusHumanscardiovascular diseasesRegistriesCoronary Artery Bypassbusiness.industryPercutaneous coronary interventionDrug-Eluting Stentsmedicine.diseaseSurgeryStenosismedicine.anatomical_structuresurgical procedures operativeTreatment OutcomeDrug-eluting stentConcomitantConventional PCICardiologyCardiology and Cardiovascular MedicinebusinessArteryEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
researchProduct

1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents

2016

Abstract Objectives The purpose of this study was to compare the 1-year outcomes of the ABSORB everolimus-eluting bioresorbable scaffold (BRS) (Abbott Vascular, Santa Clara, California) and the XIENCE everolimus-eluting stent (EES) (Abbott Vascular) in patients undergoing percutaneous coronary intervention. Background Randomized studies of the ABSORB BRS have been performed in selected patient and lesion scenarios. The available registries of the ABSORB BRS reflect real-world practice more closely compared with randomized studies, but most of them are limited by the small sample size and the lack of comparative outcomes versus second-generation drug-eluting stents. Methods A total of 1,189 …

medicine.medical_specialtyEverolimusbusiness.industrymedicine.medical_treatmentPercutaneous coronary interventionStent030204 cardiovascular system & hematologymedicine.diseaseConfidence interval03 medical and health sciences0302 clinical medicineInternal medicinePropensity score matchingConventional PCIClinical endpointmedicineCardiology030212 general & internal medicineMyocardial infarctionCardiology and Cardiovascular Medicinebusinessmedicine.drugJACC: Cardiovascular Interventions
researchProduct

Patient selection, echocardiographic screening and treatment strategies for interventional tricuspid repair using the edge-to-edge repair technique

2018

Severe tricuspid regurgitation (TR) has long been neglected despite its well-known association with mortality. While surgical mortality rates remain high in isolated tricuspid valve surgery, interventional TR repair is rapidly evolving as an alternative to cardiac surgery in selected patients at high surgical risk. Currently, interventional edge-to-edge repair is the most frequently applied technique for TR repair even though a device has not been developed for this particular indication. Due to the inherent differences in tricuspid and mitral valve anatomy and pathology, percutaneous repair of the tricuspid valve is challenging due to a variety of factors including the complexity and varia…

medicine.medical_specialtyPercutaneousProcedural approach610 Medicine & healthRegurgitation (circulation)030204 cardiovascular system & hematology2705 Cardiology and Cardiovascular Medicine03 medical and health sciences0302 clinical medicineMitral valveHumansMedicinecardiovascular diseases030212 general & internal medicineTRICUSPID VALVE REPAIRHeart Valve Prosthesis ImplantationTricuspid valvebusiness.industryPatient SelectionMitral Valve InsufficiencyTricuspid Valve InsufficiencyCardiac surgery10020 Clinic for Cardiac SurgeryTreatment Outcomemedicine.anatomical_structureEchocardiographycardiovascular systemTreatment strategyTricuspid ValveRadiologyCardiology and Cardiovascular Medicinebusiness
researchProduct

Long-term outcomes of percutaneous coronary interventions or coronary artery bypass grafting for left main coronary artery disease in octogenarians (…

2014

Percutaneous coronary intervention (PCI) with drug-eluting stents is an accepted alternative to surgery for the treatment of unprotected left main coronary artery (ULMCA) disease, but the long-term outcome in elderly patients is unclear. Aim of our study was to compare the clinical outcomes of octogenarians with ULMCA disease treated either with PCI with drug-eluting stents or coronary artery bypass grafting (CABG). The primary study end point was the composite of death, cerebrovascular accident, and myocardial infarction at follow-up. A total of 304 consecutive patients with ULMCA stenosis treated with PCI or CABG and aged 80 years were selected and analyzed in a large multinational regist…

Malemedicine.medical_treatmentMedizinCoronaryKaplan-Meier EstimateCoronary AngiographyCohort StudiesPostoperative Complications80 and overMyocardial infarctionHospital MortalityRegistriesSurvivorsAngioplasty Balloon CoronaryCoronary Artery BypassAged 80 and overEjection fractionHazard ratioAge FactorsAge Factors; Aged 80 and over; Angioplasty Balloon Coronary; Cohort Studies; Coronary Angiography; Coronary Artery Bypass; Coronary Stenosis; Coronary Vessels; Female; Geriatric Assessment; Hospital Mortality; Humans; Kaplan-Meier Estimate; Male; Percutaneous Coronary Intervention; Postoperative Complications; Prognosis; Propensity Score; Registries; Retrospective Studies; Risk Assessment; Survival Analysis; Survivors; Treatment Outcome; Drug-Eluting Stents; Cardiology and Cardiovascular MedicineDrug-Eluting StentsPrognosisCoronary Vesselssurgical procedures operativeTreatment OutcomeDrug-eluting stentCardiologyFemaleCardiology and Cardiovascular Medicinemedicine.medical_specialtyRevascularizationRisk AssessmentPercutaneous Coronary InterventionInternal medicineAngioplastymedicineHumanscardiovascular diseasesPropensity ScoreGeriatric AssessmentAgedRetrospective Studiesbusiness.industryAngioplastyCoronary StenosisPercutaneous coronary interventionmedicine.diseaseSurvival AnalysisSurgeryConventional PCIbusinessBalloon
researchProduct

Bioresorbable vascular scaffold use for coronary bifurcation lesions: A substudy from GHOST EU registry

2016

Objectives The aim of this study was to evaluate midterm outcomes of bioresorbable vascular scaffolds (BVS) implanted in bifurcation lesions. Background BVS have emerged as an alternative to conventional metallic drug-eluting stents for the treatment of coronary complex lesions. Methods Between November 2011 and January 2014, 1189 patients underwent percutaneous coronary intervention with BVS at 10 European centers (GHOST EU registry). Of these, 289 consecutive patients (302 bifurcation lesions) treated with either single-stenting (n = 260) or double-stenting (n = 42) were evaluated. Results True bifurcations were treated in 44.7%. Intravascular ultrasound and optical coherence tomography w…

Target lesionmedicine.medical_specialtyAcute coronary syndromeeducation.field_of_studymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentPopulationPercutaneous coronary interventionGeneral Medicine030204 cardiovascular system & hematologymedicine.diseaseBalloonSurgeryCoronary artery disease03 medical and health sciences0302 clinical medicineCoronary thrombosisIntravascular ultrasoundMedicineRadiology Nuclear Medicine and imaging030212 general & internal medicineCardiology and Cardiovascular MedicinebusinesseducationCatheterization and Cardiovascular Interventions
researchProduct

Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac…

2017

Aims: The aim of the study was to develop a scoring model to evaluate the quality of bioresorbable vascular scaffold (BVS) implantation and determine the model's usefulness in predicting adverse cardiac events. Methods and results: The implantation technique and clinical outcomes of 1,736 lesions treated with BVS were analysed using the GHOST-EU registry. Predilation, scaffold sizing, and post-dilation (PSP) were scored according to the hazard model derived from the weight of these variables. The primary end-point was a one-year device-oriented composite endpoint (DoCE) composed of cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularisation. Def…

Target lesionBioresorbable scaffoldmedicine.medical_specialtyAntineoplastic Agents030204 cardiovascular system & hematologyRisk AssessmentClinical research03 medical and health sciencesBlood Vessel Prosthesis ImplantationOutcome Assessment (Health Care)0302 clinical medicinePostoperative ComplicationsTheoreticalBlood vessel prosthesisModelsInternal medicineOutcome Assessment Health CaremedicineHumans030212 general & internal medicineMyocardial infarctionEverolimusAdverse effectProspective cohort studyBioresorbable scaffolds; Clinical research; Risk stratification; Antineoplastic Agents; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Everolimus; Humans; Outcome Assessment (Health Care); Retrospective Studies; Risk Assessment; Tissue Scaffolds; Models Theoretical; Postoperative Complications; Cardiology and Cardiovascular MedicineRisk stratificationRetrospective StudiesEverolimusTissue Scaffoldsbusiness.industryRetrospective cohort studyModels Theoreticalmedicine.diseaseThrombosisSurgeryBlood Vessel ProsthesisCardiologyBioresorbable scaffoldsbusinessCardiology and Cardiovascular Medicinemedicine.drug
researchProduct

1-Year Outcomes After Edge-to-Edge Valve Repair for Symptomatic Tricuspid Regurgitation

2019

Abstract Objectives The purpose of this study was to evaluate procedural and 1-year clinical and echocardiographic outcomes of patients treated with tricuspid edge-to-edge repair. Background Transcatheter edge-to-edge repair has been successfully performed in selected patients with symptomatic tricuspid regurgitation (TR) and high risk for surgery, but outcome data are sparse. Methods This analysis of the multicenter international TriValve (Transcatheter Tricuspid Valve Therapies) registry included 249 patients with severe TR treated with edge-to-edge repair in compassionate and/or off-label use. Clinical and echocardiographic outcomes were prospectively collected and retrospectively analyz…

medicine.medical_specialtyMitral regurgitationTricuspid valvebusiness.industryRenal functionRegurgitation (circulation)030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureInterquartile rangeInternal medicineConcomitantHeart failuremedicineCardiologySinus rhythm030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessJACC: Cardiovascular Interventions
researchProduct

Value of Echocardiographic Right Ventricular and Pulmonary Pressure Assessment in Predicting Transcatheter Tricuspid Repair Outcome

2020

The aim of this study was to assess the value of echocardiographic right ventricular (RV) and systolic pulmonary artery pressure (sPAP) assessment in predicting transcatheter tricuspid edge-to-edge valve repair (TTVR) outcome.RV dysfunction and pulmonary hypertension are associated with poor prognosis and are systematically sought during tricuspid regurgitation evaluation. The value of echocardiographic assessment in predicting TTVR outcome is unknown.Data were taken from the TriValve (Transcatheter Tricuspid Valve Therapies) registry, which includes patients undergoing TTVR at 14 European and North American centers. The primary outcome was 1-year survival free from hospitalization for hear…

MaleCardiac Catheterizationmedicine.medical_specialtyTime FactorsRegurgitation (circulation)Pulmonary Artery030204 cardiovascular system & hematologySeverity of Illness Index03 medical and health sciences0302 clinical medicinePrimary outcomePredictive Value of TestsInternal medicinemedicine.arteryVentricular PressureHumansMedicineArterial PressureProspective StudiesRegistries030212 general & internal medicineAgedAged 80 and overHeart FailureHospital readmissionTricuspid valvebusiness.industryRecovery of FunctionMiddle Agedmedicine.diseasePulmonary hypertensionTricuspid Valve Insufficiency3. Good healthPulmonary pressureEuropeTreatment Outcomemedicine.anatomical_structureEchocardiographyHeart failureNorth AmericaPulmonary arteryDisease ProgressionVentricular Function RightCardiologyFemaleCardiology and Cardiovascular MedicinebusinessJACC: Cardiovascular Interventions
researchProduct

Tricuspid valve repair with the Cardioband system: two-year outcomes of the multicentre, prospective TRI-REPAIR study

2021

AIMS: Tricuspid regurgitation (TR) is associated with high morbidity and mortality rates with limited treatment options. We report one- and two-year outcomes of the Cardioband tricuspid valve reconstruction system in the treatment of ≥moderate functional TR in the TRI-REPAIR study. METHODS AND RESULTS: Thirty patients were enrolled in this single-arm, multicentre, prospective study. Patients were evaluated as having ≥moderate, symptomatic functional TR and deemed inoperable due to unacceptable surgical risk. Clinical, functional, and echocardiographic data were prospectively collected up to two years (mean duration 604±227 days). At baseline, 83% were in NYHA Class III-IV, and the mean LVEF…

Cardiac Catheterizationmedicine.medical_specialtyTime Factors030204 cardiovascular system & hematologySeverity of Illness Index03 medical and health sciences0302 clinical medicineQuality of lifeClinical ResearchInternal medicineHumansMedicineIn patientProspective Studies030212 general & internal medicineTRICUSPID VALVE REPAIRProspective cohort studyRetrospective StudiesHeart Valve Prosthesis ImplantationEjection fractionTricuspid valvebusiness.industryWalk distanceMortality rateTricuspid Valve InsufficiencyTreatment Outcomemedicine.anatomical_structureCardiologyTricuspid ValveCardiology and Cardiovascular MedicinebusinessEuroIntervention
researchProduct

TCT-419 Usefulness of a scoring system for predicting adverse cardiovascular events in patients undergoing everolimus-eluting bioresorbable scaffolds…

2016

medicine.medical_specialtyScoring systemEverolimusbusiness.industry030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinemedicineIn patient030212 general & internal medicineRadiologyCardiology and Cardiovascular MedicinebusinessBioresorbable scaffoldmedicine.drugJournal of the American College of Cardiology
researchProduct

Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-Year fo…

2017

Objectives to compare the 1-year outcome between bioresorbable vascular scaffold (BVS), everolimus-eluting stent (EES), and drug-eluting balloon (DEB) for in-stent restenosis (ISR) treatment. Background BVS has been proposed as alternative for ISR treatment. To date a direct comparison between BVS and DES or DEB for ISR treatment is lacking. Methods We retrospectively analyzed all ISR lesions treated with BVS, DEB, and EES from January 2012 to December 2014. A total of 548 lesions (498 patients) were included. By applying two propensity-score matching, 93 lesions treated with BVS were compared with 93 lesions treated with DEB, and 100 lesions treated with BVS were compared to 100 lesions tr…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentUrology030204 cardiovascular system & hematologyProsthesis DesignBalloonRisk AssessmentCardiac CathetersCoronary Restenosis03 medical and health sciences0302 clinical medicineCoated Materials BiocompatibleRestenosisRisk FactorsAbsorbable ImplantsmedicineHumansRadiology Nuclear Medicine and imagingEverolimus030212 general & internal medicineAngioplasty Balloon CoronaryPropensity ScoreAgedRetrospective StudiesBioresorbable vascular scaffoldin stent restenosibusiness.industryIncidence (epidemiology)percutaneous coronary interventionStentPercutaneous coronary interventionCardiovascular AgentsDrug-Eluting StentsGeneral MedicineMiddle Agedmedicine.diseaseTreatment OutcomeItalyDrug-eluting stentPropensity score matchingFemalebioresorbable vascular scaffolddrug eluting balloonCardiology and Cardiovascular Medicinebusinessdrug eluting stent
researchProduct

Anatomical and procedural features associated with aortic root rupture during balloon-expandable transcatheter aortic valve replacement

2013

Background— Aortic root rupture is a major concern with balloon-expandable transcatheter aortic valve replacement (TAVR). We sought to identify predictors of aortic root rupture during balloon-expandable TAVR by using multidetector computed tomography. Methods and Results— Thirty-one consecutive patients who experienced left ventricular outflow tract (LVOT)/annular/aortic contained/noncontained rupture during TAVR were collected from 16 centers. A caliper-matched sample of 31 consecutive patients without annular rupture, who underwent pre-TAVR multidetector computed tomography served as a control group. Multidetector computed tomography assessment included short- and long-axis diameters an…

Malemedicine.medical_specialtyCardiac CatheterizationTranscatheter aorticAortic rootmedicine.medical_treatmentAortic Rupturemultidetector computed tomographySettore MED/11 - Malattie dell'Apparato CardiovascolareCohort StudiesValve replacementPredictive Value of TestsRisk FactorsPhysiology (medical)Internal medicineMultidetector computed tomographymedicine80 and overVentricular outflow tractHumanscardiovascular diseasesannular calcification; annular rupture; multidetector computed tomography; transcatheter heart valves; Aged; Aged 80 and over; Angioplasty Balloon; Aortic Rupture; Aortic Valve; Aortic Valve Stenosis; Calcinosis; Cohort Studies; Female; Heart Valve Prosthesis Implantation; Humans; Logistic Models; Male; Predictive Value of Tests; Risk Factors; Tomography X-Ray Computed; Cardiac CatheterizationTomographyAgedAged 80 and overHeart Valve Prosthesis Implantationbusiness.industrySinotubular JunctionAngioplastyCalcinosisAortic Valve Stenosismedicine.diseaseX-Ray ComputedBalloon expandable stentLogistic Modelstranscatheter heart valvesAortic ValveCardiologycardiovascular systemannular ruptureFemaleRadiologyCardiology and Cardiovascular MedicinebusinessTomography X-Ray ComputedAngioplasty BalloonBalloonCalcificationannular calcification
researchProduct

Twelve-month outcomes after bioresorbable vascular scaffold implantation in patients with acute coronary syndromes. Data from the European Multicente…

2017

The aim of this study was to report on the midterm outcomes of patients undergoing percutaneous coronary intervention with bioresorbable vascular scaffolds (BVS) for the treatment of acute coronary syndromes (ACS) and compare with those of patients with stable coronary artery disease (sCAD).One thousand four hundred and seventy-seven (1,477) patients underwent implantation of one or more BVS (Absorb BVS; Abbott Vascular, Santa Clara, CA, USA) at 11 European centres and were included in the GHOST-EU registry. Admissions comprised 47.1% of the patients (951 BVS) with ACS, and 52.8% (1,274 BVS) with sCAD. During a median follow-up of 384 (359-460) days, patient-oriented endpoints (PoCE), inclu…

Target lesionMaleAcute coronary syndromemedicine.medical_specialtymedicine.medical_treatmentInfarctionCoronary Artery Disease030204 cardiovascular system & hematologyCoronary artery disease03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionInternal medicineMedicineHumans030212 general & internal medicineRegistriesAcute Coronary SyndromeAgedRetrospective StudiesTissue Scaffoldsbusiness.industryUnstable anginaIncidence (epidemiology)Percutaneous coronary interventionMiddle Agedmedicine.diseaseThrombosisTreatment OutcomeCardiologyFemaleCardiology and Cardiovascular MedicinebusinessEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
researchProduct

Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical …

2016

Background Overlapping implantation of bioresorbable scaffolds (BRSs) are frequent in long coronary lesions. Its impact on clinical outcomes is unknown. Objective: To compare the clinical outcomes of patients treated with overlapping BRS with those patients treated with no-overlap BRS. Methods: We analyzed the 1-year clinical outcomes of 1,477 patients treated with BRS in the GHOST-EU registry, according to the implantation of overlapping BRS. Primary endpoint was patient oriented composite endpoint (PoCE) of: all-cause death, any myocardial infarction (MI) and any repeated revascularization. Scaffold thrombosis, according to Academic Research Consortium definition, was also analyzed. Resul…

medicine.medical_specialtymedicine.medical_treatment030204 cardiovascular system & hematologyRevascularizationCoronary artery diseaseLesion03 medical and health sciences0302 clinical medicineInternal medicinemedicineClinical endpointRadiology Nuclear Medicine and imaging030212 general & internal medicineMyocardial infarctionEverolimusbusiness.industryfungiPercutaneous coronary interventionGeneral Medicinemedicine.diseaseThrombosisCardiologymedicine.symptomCardiology and Cardiovascular Medicinebusinessmedicine.drugCatheterization and Cardiovascular Interventions
researchProduct

A multicentre European registry to evaluate the Direct Flow Medical transcatheter aortic valve system for the treatment of patients with severe aorti…

2016

Aims Our aim was to assess the clinical outcomes of the Direct Flow Medical Transcatheter Aortic Valve System (DFM-TAVS), when used in routine clinical practice. Methods and results This is a prospective, open-label, multicentre, post-market registry of patients treated with DFM-TAVS according to approved commercial indications. Echocardiographic and angiographic data were evaluated by an independent core laboratory and adverse events were adjudicated and classified according to VARC-2 criteria by an independent clinical events committee. The primary endpoint was freedom from all-cause mortality at 30 days post procedure. Secondary endpoints included procedural, early safety and efficacy en…

Aortic valveMalemedicine.medical_specialtyCardiac Catheterizationmedicine.medical_treatmentAortic Valve InsufficiencyRegurgitation (circulation)030204 cardiovascular system & hematologyTranscatheter Aortic Valve Replacement03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineClinical endpointHumans030212 general & internal medicineHeart valveProspective StudiesRegistriesCardiac catheterizationAgedAged 80 and overHeart Valve Prosthesis Implantationbusiness.industryAortic Valve Stenosismedicine.disease3. Good healthClinical trialStenosismedicine.anatomical_structureTreatment OutcomeAortic valve stenosisAortic ValveHeart Valve ProsthesisCardiologyFemaleCardiology and Cardiovascular MedicinebusinessEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
researchProduct

Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions

2017

Abstract Objectives The authors sought to investigate 1-year outcomes in patients treated with bioresorbable everolimus-eluting vascular scaffolds (BVS) for “long coronary lesions.” Background The present substudy derived from the GHOST-EU registry included 1,722 lesions in 1,468 consecutive patients, enrolled between November 2011 and September 2014 at 11 European centers. Methods The lesions were divided into 3 groups according to continuous BVS length: 1) shorter than 30 mm; 2) between 30 and 60 mm; and 3) longer than 60 mm. Primary device-oriented endpoint (target lesion failure [TLF]) was defined as a combination of cardiovascular death, target vessel myocardial infarction, or clinical…

Target lesionmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentPercutaneous coronary intervention030204 cardiovascular system & hematologymedicine.diseaseSurgeryCoronary artery diseaseLesion03 medical and health sciences0302 clinical medicineCoronary thrombosisInterquartile rangeCardiovascular agentMedicine030212 general & internal medicineMyocardial infarctionmedicine.symptomCardiology and Cardiovascular MedicinebusinessJACC: Cardiovascular Interventions
researchProduct

Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds : a European perspective

2015

Aims Next to patient characteristics, the lack of a standardised approach for bioresorbable vascular scaffold (BVS) implantation is perceived as a potential explanation for the heterogeneous results reported so far. To provide some guidance, we sought to find a consensus on the best practices for BVS implantation and management across a broad array of patient and lesion scenarios. Methods and results Fourteen European centres with a high volume of BVS procedures combined their efforts in an informal collaboration. To get the most objective snapshot of different practices among the participating centres, a survey with 45 multiple choice questions was prepared and conducted. The results of th…

Diagnostic Imagingmedicine.medical_specialtyConsensusBest practiceMEDLINEPatient characteristicsConsensus criteriaCoronary Artery DiseaseProsthesis DesignPercutaneous Coronary InterventionPredictive Value of TestsRisk FactorsSurveys and QuestionnairesAbsorbable ImplantsmedicineHumansMedical physicsPractice Patterns Physicians'Multiple choiceBioresorbable vascular scaffoldbusiness.industryPatient SelectionSurgeryEuropeTreatment OutcomeHealth Care SurveysCardiology and Cardiovascular MedicinebusinessBioresorbable scaffoldIntravascular imagingHospitals High-Volume
researchProduct

TCT-437 Clinical outcome of coronary bifurcation management with a “fully bioresorbable” technique. Results of the multicentre BBS study

2016

medicine.medical_specialtybusiness.industry030204 cardiovascular system & hematologymedicine.diseaseOutcome (game theory)03 medical and health sciences0302 clinical medicineEmergency medicinemedicine030212 general & internal medicineMedical emergencyCardiology and Cardiovascular MedicinebusinessCoronary bifurcationJournal of the American College of Cardiology
researchProduct

Six-Month Outcomes of the Tri-Repair Study Assessing the Cardioband Tricuspid Valve Reconstruction System for Patients with Severe Tricuspid Regurgit…

2018

Background: Severe tricuspid regurgitation (TR) is associated with high morbidity and mortality rates with limited treatment options. We report the six-month safety and performance of the Cardioband™ Tricuspid Valve Reconstruction System in the treatment of severe functional TR in 30 patients enrolled in the TRI-REPAIR study. Methods: Between October 2016 and July 2017, 30 patients were enrolled in this single-arm, multicenter, prospective trial. Patients were diagnosed with severe, symptomatic TR in the absence of untreated left-heart disease and deemed inoperable because of unacceptable risk for open-heart surgery by the local heart team. Clinical, functional, and echocardiographic data w…

medicine.medical_specialtyTricuspid valveEjection fractionVena contractabusiness.industryMortality ratemedicine.diseaseClinical trialmedicine.anatomical_structureQuality of lifeInternal medicineHeart failureGood clinical practicemedicinebusinessSSRN Electronic Journal
researchProduct

Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry.

2016

Aims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subset, with higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long term, but their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA), left anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular death, target vessel m…

LCX (29Target lesionMale52%). Patients presenting with ostial lesions did not differ from the remaining cohort except for a higher incidence of prior revascularisation. Predilation was performed in 97% of the lesions (vs. 96% in non-ostialp= 0.035)medicine.medical_treatmentMyocardial Infarction304 patients with a mean age of 62 +/- 11years. There were 90 ostial lesions (5.8%) in 84 patients (6.4%) located at the ostial RCA (14Coronary Artery Disease030204 cardiovascular system & hematologyCoronary artery diseasebut their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA)0302 clinical medicineAbsorbable Implants030212 general & internal medicineMyocardial infarctionCircumflexRegistriesTissue Scaffolds32%)Drug-Eluting StentsMiddle AgedThrombosisCoronary VesselsAims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subset with higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long term but their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA) left anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular death target vessel myocardial infarction or target lesion revascularisation. The database included a total of 1549 lesions in 1304 patients with a mean age of 62 +/- 11years. There were 90 ostial lesions (5.8%) in 84 patients (6.4%) located at the ostial RCA (14; 16%) LCX (29; 32%) or LAD (47; 52%). Patients presenting with ostial lesions did not differ from the remaining cohort except for a higher incidence of prior revascularisation. Predilation was performed in 97% of the lesions (vs. 96% in non-ostial p= 0.618) post-dilation in 43% (versus 58% in the non-ostial group p= 0.008). At quantitative coronary angiography treatment of ostial lesions was associated with higher residual stenosis (30% [23-41] vs. 26% [20-37] p= 0.035) but no difference in minimum lumen diameter existed (p= 0.447). Follow-up data were available at 385 [362-465] days. The 12-month Kaplan-Meier estimated rates of scaffold thrombosis were 4.9% and 2.0% (ostial and non-ostial lesion groups respectively log-rank p= 0.005). The device-oriented composite endpoint occurred respectively in 12.6% and 4.6% at 12 months (log-rank p= 0.001). Treatment of ostial lesions was an independent predictor of this endpoint (p= 0.0025 HR 2.65 [1.41-4.97]).OstiumAims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subsetTreatment Outcomein 12.6% and 4.6% at 12 months (log-rank p= 0.001). Treatment of ostial lesions was an independent predictor of this endpoint (p= 0.0025CardiologyFemale549 lesions in 1medicine.symptomCardiology and Cardiovascular MedicineAdultpost-dilation in 43% (versus 58% in the non-ostial groupmedicine.medical_specialtyor LAD (47HR 2.65 [1.41-4.97])but no difference in minimum lumen diameter existed (p= 0.447). Follow-up data were available at 385 [362-465] days. The 12-month Kaplan-Meier estimated rates of scaffold thrombosis were 4.9% and 2.0% (ostial and non-ostial lesion groupsrespectivelyLesion03 medical and health sciencesPercutaneous Coronary Interventionwith higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long termleft anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular deathInternal medicinemedicineHumanstarget vessel myocardial infarction or target lesion revascularisation. The database included a total of 1Agedp= 0.008). At quantitative coronary angiographybusiness.industryPercutaneous coronary interventionp= 0.618)treatment of ostial lesions was associated with higher residual stenosis (30% [23-41] vs. 26% [20-37]log-rank p= 0.005). The device-oriented composite endpoint occurredmedicine.diseaseSurgery16%)businessEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
researchProduct

Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes …

2015

Clinical data on the early and midterm outcomes of bioresorbable vascular scaffolds (BVS) in routine clinical practice are limited. To fill this gap, we report on the early and midterm clinical outcomes of PCI with everolimus-eluting BVS from the large multicentre GHOST-EU registry.Between November 2011 and January 2014, 1,189 patients underwent percutaneous coronary intervention with one or more BVS (Absorb BVS; Abbott Vascular, Santa Clara, CA, USA) at 10 European centres. The primary outcome of interest was target lesion failure (TLF), defined as the combination of cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularisation (TLR). A total of 1…

MaleReoperationTarget lesionmedicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionAntineoplastic AgentsComorbidityCoronary Artery DiseaseAngina PectorisPercutaneous Coronary InterventionRisk FactorsInterquartile rangeInternal medicineAbsorbable ImplantsDiabetes MellitusmedicineHumansCumulative incidenceEverolimusMyocardial infarctionAcute Coronary SyndromeAgedProportional Hazards ModelsTissue Scaffoldsbusiness.industryHazard ratioPercutaneous coronary interventionDrug-Eluting StentsThrombosisMiddle Agedmedicine.diseaseThrombosisSurgeryEuropeTreatment OutcomeCardiovascular DiseasesConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinessEuroIntervention
researchProduct

Outcomes of transcatheter tricuspid valve intervention by right ventricular function: a multicentre propensity-matched analysis

2021

BACKGROUND Tricuspid regurgitation (TR) has a poor prognosis and limited treatment options and is frequently accompanied by right ventricular (RV) dysfunction. Transcatheter tricuspid valve interventions (TTVI) to reduce TR have been shown to be safe and feasible with encouraging early results. Patient selection for TTVI remains challenging, with the role of right ventricular (RV) function being unknown. AIMS The aims of this study were 1) to investigate survival in a TTVI-treated patient population and a conservatively treated TR population, and 2) to evaluate the outcome of TTVI as compared to conservative treatment stratified according to the degree of RV function. METHODS We studied 684…

medicine.medical_specialtyeducation.field_of_studyTricuspid valveVentricular functionbusiness.industryVentricular Dysfunction RightMortality rateHazard ratioPopulationTertiary careTricuspid Valve InsufficiencyTreatment Outcomemedicine.anatomical_structureInternal medicinePropensity score matchingCohortVentricular Function RightmedicineCardiologyHumansTricuspid ValveCardiology and Cardiovascular MedicineeducationbusinessEuroIntervention
researchProduct

Effect of implantation technique on outcomes in patients receiving bioresorbable scaffolds in various clinical scenarios

2021

ABSTRACT Introduction and objectives: The PSP (pre-dilation, sizing and post-dilation) score, derived from the GHOST-EU registry, has evaluated the relationship between the implantation technique of bioresorbable scaffolds and the clinical outcomes. The objective was to perform an external validation of the PSP technique and to determine its effect on adverse cardiac events in various clinical and anatomical scenarios. Methods: Data from the REPARA registry (2230 patients) were used for external validation, whereas a common database combining REPARA and GHOST-EU (3250 patients) data was used to evaluate the effect of PSP technique in various clinical and anatomical scenarios. PSP-1 and PSP-…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentRPercutaneous coronary interventionmedicine.diseaseCoronary artery diseaseeye diseasesPercutaneous coronary interventionSurgeryCoronary artery diseaseBioresorbable vascular scaffoldsBioresorbable scaffoldsmedicineMedicineIn patientCardiology and Cardiovascular MedicinebusinessBioresorbable scaffoldREC: interventional cardiology (English Edition)
researchProduct

Drug-Eluting Stent for Left Main Coronary Artery Disease

2012

Objectives The aim of this study was to compare, in a large all-comers registry, major adverse cardiac and cerebrovascular events (MACCE) after percutaneous coronary intervention (PCI) with first-generation drug-eluting stents (DES) versus coronary artery bypass grafting (CABG) in unprotected left main coronary artery (ULMCA) stenosis. Background Percutaneous coronary intervention with DES implantation in ULMCA has been shown to be a feasible and safe approach at midterm clinical follow-up. Methods All consecutive patients with ULMCA stenosis treated by PCI with DES versus CABG were analyzed in this multinational registry. A propensity score analysis was performed to adjust for baseline dif…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentHazard ratioPercutaneous coronary interventionEuroSCOREmedicine.diseaseSurgeryCoronary artery diseasesurgical procedures operativeDrug-eluting stentAngioplastyInternal medicineConventional PCImedicineCardiologycardiovascular diseasesMyocardial infarctionbusinessCardiology and Cardiovascular MedicineJACC: Cardiovascular Interventions
researchProduct

Computing Methods for Composite Clinical Endpoints in Unprotected Left Main Coronary Artery Revascularization

2016

Abstract Objectives The study sought to investigate the impact of different computing methods for composite endpoints other than time-to-event (TTE) statistics in a large, multicenter registry of unprotected left main coronary artery (ULMCA) disease. Background TTE statistics for composite outcome measures used in ULMCA studies consider only the first event, and all the contributory outcomes are handled as if of equal importance. Methods The TTE, Andersen-Gill, win ratio (WR), competing risk, and weighted composite endpoint (WCE) computing methods were applied to ULMCA patients revascularized by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) at 14 interna…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentPercutaneous coronary interventionInfarction030204 cardiovascular system & hematologymedicine.diseaseRevascularization03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicineConventional PCIPost-hoc analysismedicineClinical endpointCardiology030212 general & internal medicineMyocardial infarctionCardiology and Cardiovascular MedicinebusinessJACC: Cardiovascular Interventions
researchProduct

Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds: a subanalysis of the European Multicentre …

2017

Background Data on the clinical performance of bioresorbable scaffolds in patients with diabetes mellitus (DM) are still limited. The present study reported 1-year clinical outcomes associated with the use of everolimus-eluting bioresorbable vascular scaffolds (Absorb BVS; Abbott Vascular, Santa Clara, CA) in DM patients. Methods and Results This was a subanalysis from the GHOST-EU (Gauging coronary Healing with biOresorbable Scaffolding plaTforms in Europe) multicenter retrospective registry including patients treated with Absorb BVS between November 2011 and September 2014. In this study, a comparative analysis stratified according to DM was performed. The primary endpoint was target lesi…

Target lesionMaleTime Factorsmedicine.medical_treatmentCoronary Artery Disease030204 cardiovascular system & hematologyCoronary Angiography0302 clinical medicineRisk FactorsNuclear Medicine and ImagingAbsorbable ImplantsClinical endpoint030212 general & internal medicineMyocardial infarctionRegistriesdiabetesClinical performanceGeneral MedicineMiddle AgedThrombosisbioresorbable vascular scaffoldsclinical outcomesEuropeTreatment Outcomebioresorbable vascular scaffolds; clinical outcomes; diabetes; Radiology Nuclear Medicine and Imaging; Cardiology and Cardiovascular MedicineCardiologyFemaleRadiologyCardiology and Cardiovascular Medicinemedicine.medical_specialtyRevascularizationProsthesis Design03 medical and health sciencesPercutaneous Coronary InterventionInternal medicineDiabetes mellitusmedicineDiabetes MellitusHumansRadiology Nuclear Medicine and imagingIn patientEverolimusAgedRetrospective Studiesbusiness.industryCoronary ThrombosisCardiovascular Agentsmedicine.diseaseSurgerybusinessCatheterization and cardiovascular interventions : official journal of the Society for Cardiac AngiographyInterventions
researchProduct